Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11826628 | 0.86 | KMT2A (0.75) | KMT2ARXFP1MAPK1MEN1L3MBTL1 | |
| SCHEMBL11828722 | 0.86 | KMT2A (0.75) | KMT2ARXFP1MAPK1MEN1L3MBTL1 | |
| SCHEMBL15003907 | 0.84 | KMT2A (0.72) | KMT2ARXFP1MAPK1MEN1L3MBTL1 | |
| SCHEMBL2403877 | 0.76 | ADORA2B (0.69) | KMT2ARXFP1MAPK1MEN1CYP2C19 | |
| SCHEMBL2704481 | 0.75 | KMT2A (0.59) | KMT2ARXFP1MAPK1MEN1L3MBTL1 | |
| SCHEMBL25220723 | 0.74 | MAPK1 (1.00) | KMT2ARXFP1MAPK1MEN1L3MBTL1 | |
| SCHEMBL21750507 | 0.74 | KMT2A (0.57) | KMT2ARXFP1MAPK1MEN1CYP2C19 | |
| SCHEMBL13082622 | 0.74 | KMT2A (0.57) | KMT2ARXFP1MEN1L3MBTL1CYP2C19 | |
| SCHEMBL17475359 | 0.73 | KMT2A (0.58) | KMT2ARXFP1MAPK1MEN1L3MBTL1 | |
| SCHEMBL22398941 | 0.73 | KMT2A (0.58) | KMT2ARXFP1MAPK1MEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216430-A1 | CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2020-07-09 | — | — | US | disclosed |
| WO-2019060998-A1 | CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2019-04-04 | — | — | WO | disclosed |
| WO-2018045464-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216430-A1 | CATALYST-FREE AND REDOX-NEUTRAL INNATE TRIFLUOROMETHYLATION AND ALKYLATION OF (HETERO)AROMATICS ENABLED BY LIGHT | CYBB, NOX4, NOX3 | KMT2A 1763/4885RXFP1 4704/4885MAPK1 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.